iGRO™ supports individualised GH treatment for short children born small for gestational age (SGA) as soon as treatment starts.
It is a web-based medical device designed to be used in clinical practice — to predict how much a child may grow in the first and subsequent years of GH therapy.
It can be used to calculate growth predictions for children with Turner syndrome (TS) and provides evidence-based guidance and justification for GH treatment decisions.
It can be used to calculate growth predictions for short children born small for gestational age (SGA) and provides evidence-based guidance and justification for GH treatment decisions.
iGRO™ prediction algorithms can explain 30-52%1 of variability in growth responses to GH treatment for short children born SGA.
iGRO™ requires standard data that is routinely collected during clinic visits:
- Birth date
- Gender
- Primary diagnosis
- Birth weight
- Parents’ heights
- Height
- Weight
- Treatment start date
- GH dose
1- Ranke, Michael B., et al. "Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database)." The Journal of Clinical Endocrinology & Metabolism 88.1 (2003): 125-131.